Lonza Group Ltd
LO3A
Company Profile
Business description
Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
Contact
Muenchensteinerstrasse 38
Basel4002
CHET: +41 613168111
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
19,299
Stocks News & Analysis
stocks
ASX reporting season wrap: BHP, banks, CSL bloodbath and more
A round up of notable stories and reactions as ASX earnings season continues.
stocks
Stock showdown: How do ASX healthcare giants compare on key investing criteria?
Our healthcare analyst Shane Ponraj helps me compare the moatiness and growth prospects of two sector heavyweights.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,284.20 | 51.60 | 0.56% |
| CAC 40 | 7,938.29 | 34.74 | -0.44% |
| DAX 40 | 24,293.34 | 16.37 | 0.07% |
| Dow JONES (US) | 44,785.50 | 152.81 | -0.34% |
| FTSE 100 | 9,309.20 | 21.06 | 0.23% |
| HKSE | 25,104.61 | 61.33 | -0.24% |
| NASDAQ | 21,100.31 | 72.54 | -0.34% |
| Nikkei 225 | 42,610.17 | 278.38 | -0.65% |
| NZX 50 Index | 13,194.07 | 122.77 | 0.94% |
| S&P 500 | 6,370.17 | 25.61 | -0.40% |
| S&P/ASX 200 | 9,019.10 | 45.40 | 0.51% |
| SSE Composite Index | 3,771.10 | 4.89 | 0.13% |